Baker Brothers Life Sciences LP (CIK 1363364) reported 112 SEC Form 4 insider transactions across 12 companies over the past 18 months (most recent 2026-07-02). Recent activity: Buy INCY (400 shares), Buy INCY (400 shares), Buy MDGL (908 shares), Buy MDGL (908 shares), Buy INCY (1,642 shares). Source: SEC Form 4.
| Date | Company | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-07-02 | INCYTE CORP (INCY) | Director | Buy | 400 | $0 |
| 2026-07-02 | INCYTE CORP (INCY) | Director | Buy | 400 | $0 |
| 2026-06-18 | MADRIGAL PHARMACEUTICALS, INC. (MDGL) | Director | Buy | 908 | $0 |
| 2026-06-18 | MADRIGAL PHARMACEUTICALS, INC. (MDGL) | Director | Buy | 908 | $0 |
| 2026-06-10 | INCYTE CORP (INCY) | Director | Buy | 1,642 | $0 |
| 2026-06-10 | INCYTE CORP (INCY) | Director | Buy | 1,642 | $0 |
| 2026-06-05 | Denali Therapeutics Inc. (DNLI) | Director | Buy | 6,408 | $0 |
| 2026-06-05 | Denali Therapeutics Inc. (DNLI) | Director | Buy | 6,408 | $0 |
| 2026-06-02 | ACADIA PHARMACEUTICALS INC (ACAD) | Director | Buy | 18,622 | $0 |
| 2026-06-02 | Kiniksa Pharmaceuticals International, plc (KNSA) | Director | Buy | 6,078 | $0 |
| 2026-06-02 | ACADIA PHARMACEUTICALS INC (ACAD) | Director | Buy | 18,622 | $0 |
| 2026-06-02 | Kiniksa Pharmaceuticals International, plc (KNSA) | Director | Buy | 6,078 | $0 |
| 2026-05-11 | INCYTE CORP (INCY) | Director | Buy | 15,000 | $1.3M |
| 2026-05-11 | INCYTE CORP (INCY) | Director | Buy | 15,000 | $1.3M |
| 2026-04-02 | INCYTE CORP (INCY) | Director | Buy | 421 | $0 |
| 2026-04-02 | INCYTE CORP (INCY) | Director | Buy | 421 | $0 |
| 2026-01-06 | BICYCLE THERAPEUTICS PLC (BCYC) | Director | Buy | 19,000 | $0 |
| 2026-01-06 | BICYCLE THERAPEUTICS PLC (BCYC) | Director | Buy | 19,000 | $0 |
| 2026-01-05 | INCYTE CORP (INCY) | Director | Buy | 328 | $0 |
| 2026-01-05 | INCYTE CORP (INCY) | Director | Buy | 328 | $0 |
| 2025-12-19 | Kodiak Sciences Inc. (KOD) | Director | Buy | 217,428 | $5.0M |
| 2025-12-19 | Kodiak Sciences Inc. (KOD) | Director | Buy | 2.4M | $55.0M |
| 2025-12-11 | Kymera Therapeutics, Inc. (KYMR) | Director | Buy | 167,192 | $14.4M |
| 2025-12-11 | Kymera Therapeutics, Inc. (KYMR) | Director | Buy | 1.8M | $158.1M |
| 2025-10-02 | INCYTE CORP (INCY) | Director | Buy | 388 | $0 |
Source: SEC Form 4 filings · as of 2026-07-02